The FDA Is Talking About Peptides. Here's What Consumers Should Really Take Away

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) held one of the most closely watched meetings in health and wellness this year. Over two days at the agency's Silver Spring, MD headquarters, the committee reviewed seven peptides that have built a large consumer following on claims related to recovery, inflammation, metabolism, longevity, cognitive health, and sleep: BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and Emideltide (DSIP).

By the end of the second day, the committee had voted to recommend six of the seven for possible addition to the FDA's 503A Bulk Drug Substances List, the list that determines which ingredients licensed compounding pharmacies may prepare against a prescription. Emideltide (DSIP) was the one peptide the committee declined to advance.

The headlines came fast.

"Peptides are back." "FDA clears peptides." "Peptides win."

Almost none of them captured what actually happened in the room, or what it means for consumers deciding whether to trust a peptide-based product.

The Meeting Wasn't About Whether Peptides Work

It was about whether specific peptides should be eligible for pharmacy compounding, a narrower and more technical question than whether they're proven safe and effective.

For context, there are a few key pieces of information that deserve clarity and precision, since they got flattened or obscured in most coverage:

• The votes were non-binding recommendations, not approvals. The FDA is not required to follow them, and has broken with this committee's recommendations before.
• The votes were close. BPC-157, KPV, and TB-500 each passed 8 to 6 with one abstention; MOTS-c passed 7 to 5 with two abstentions. This was not a consensus endorsement.
• The committee overruled its own agency's scientists. FDA staff reviewers had recommended against advancing all seven peptides, citing insufficient data. The committee weighed that guidance against public testimony, including from clinicians affiliated with telehealth and wellness companies with a commercial stake in wider peptide access, and voted to proceed anyway on six of the seven.
• Even a favorable recommendation doesn't make these approved medicines. Reaching the 503A Bulks List requires a formal rulemaking process that, realistically, extends into 2027. Nothing became legal to compound the day after the vote that wasn't legal the day before.

The Most Important Conversation Happened Behind the Vote

The part of the meeting that got the least attention was arguably the most important: what FDA's own scientists actually said about the evidence.

Across the briefing documents, FDA staff repeatedly flagged the same limitations:

• Limited or absent human clinical trial data for several of the peptides.
• Small, open-label, or poorly controlled studies where data did exist.
• No universally accepted chemical definition or standardized formula for some peptides, meaning products sold under the same name may not contain the same active molecule.
• Manufacturing and product-characterization inconsistencies that complicate any safety or efficacy assessment.
• Adverse event reports in FDA's surveillance database that couldn't be conclusively attributed to the peptides themselves, due to confounding factors like concurrent medication use.

Supporters on the committee generally argued that, absent of proof these peptides are unsafe, restricting access simply pushes consumers toward unregulated gray-market suppliers, arguably the more dangerous outcome. Critics countered that a favorable vote risks being misread by the public as a scientific endorsement, when in fact the underlying clinical evidence for most of these compounds remains thin.

Both things can be true. And that tension is exactly why the conclusion consumers should draw isn't "peptides are approved" or "peptides are safe" — it's: every peptide needs to be evaluated individually, on the strength of its own evidence.

A Peptide Is a Category, Not a Claim

"Peptide" has become a marketing word. Scientifically, it describes something much broader.

Peptides are short chains of amino acids. Thousands occur naturally in the human body, functioning as signaling molecules involved in hormone regulation, wound healing, immune response, and structural support. Because the category is so broad, there's no such thing as a "typical peptide" — each one has its own biological function, application, and research history.

Some are early-stage investigational compounds with little more than animal data or online testimonials behind them. Others have decades of published, peer-reviewed research, including randomized, placebo-controlled human trials.

That distinction, not whether a label says "peptide," is what matters.

The Questions We Should Be Asking

As more peptide-based products reach the market, it's worth asking the same questions researchers ask before drawing conclusions:

Question	Why It Matters	What to Look For
Has this peptide been studied in humans?	Animal and cell data doesn't reliably predict human outcomes	Published human clinical trials, not just preclinical research
Were studies randomized and placebo-controlled?	Controls for placebo effect and researcher bias	Double-blind, placebo-controlled trial design
Were outcomes measured with objective tools?	Self-reported impressions are unreliable measures of efficacy	Standardized clinical measurements, not just surveys
Were results statistically significant?	Separates real effects from chance variation	Reported p-values and effect sizes in study data
Have findings been independently reproduced?	Single studies can be anomalies; replication builds confidence	Multiple independent studies reaching similar conclusions

Evidence exists on a spectrum, and not every peptide sits in the same place on it. A product built around a well-characterized, clinically studied peptide is a fundamentally different proposition than one built around a compound the FDA itself says lacks basic chemical standardization.

What Evidence-Based Peptide Science Looks Like

At OMI, we think peptide-based products should be judged the way researchers judge them: by measurable clinical outcomes, not category membership.

OMI Hair Growth Peptides are formulated with naturally derived, bioavailable keratin peptides that have been evaluated in two randomized, double-blind, placebo-controlled human clinical trials measuring objective indicators of hair quality.

OMI Hair Growth Peptides: Clinical Trials

In the first double-blind, placebo-controlled clinical study, women with damaged hair received a keratin peptide formulation over 90 days. Compared with placebo, the trial found:

• A 46.6% reduction in hair shedding, measured by standardized hair pull testing.
• A 9.2% improvement in the anagen-to-telogen ratio, indicating a greater proportion of hairs in the active growth phase.
• A 5.9% improvement in hair tensile strength.
• Statistically significant improvement in overall hair appearance versus placebo.

The second randomized, placebo-controlled trial evaluated women aged 45 to 60 with stressed or damaged hair. After 60 days:

• Hair loss was reduced by 43.1%, measured by standardized hair pull testing.
• Hair cortex structural integrity improved by 17.6%, measured using polarized imaging to assess keratin organization within the hair fiber.

Notably, the investigators also reported outcomes that did not differ significantly from placebo, including hair luminosity and luster. Reporting the null results alongside the positive ones is part of what makes a clinical trial trustworthy rather than promotional.

The Future of Peptides Depends on Better Science

The July 2026 PCAC meeting will likely be remembered as a milestone, not because it settled the underlying science, but because it made official just how much regulatory and commercial interest now surrounds peptide therapies, and how far the evidence still has to go to catch up with the demand.

Consumers increasingly aren't satisfied with products sold on possibility alone. They're asking whether a product's specific ingredient has demonstrated a meaningful benefit in a well-designed human clinical trial, not just whether "peptide" appears on the label.

Looking Beyond the Headlines

The PCAC meeting was never really a referendum on whether peptides are "good" or "bad" as a category. It was a case-by-case evaluation of individual ingredients against the evidence available for each one. That's the same standard that should guide any purchasing decision.

For OMI Hair Growth Peptides, that standard is met with two randomized, placebo-controlled human clinical trials demonstrating measurable improvements in hair shedding, growth-phase activity, fiber strength, and structural integrity.

As peptide science evolves, and as the FDA works through a rulemaking process that will play out over the next year or more, consumers deserve what researchers already demand of themselves: clear evidence, transparent reporting, and clinically meaningful results.

This article reflects publicly reported outcomes of the FDA's July 2026 Pharmacy Compounding Advisory Committee meeting. Advisory committee recommendations are non-binding and do not constitute FDA approval of any peptide for any use. 

Frequently Asked Questions

Are peptides for hair growth safe?

Peptides are naturally occurring molecules your body already makes and recognizes, and this is part of what makes them well-tolerated for most people. Keratin peptides like IFP-131™ are drug-free, hormone-free, and synthetic-free. As with any supplement, it's always a good idea to check with your healthcare provider if you're pregnant, nursing, or taking medications.

How do peptides support hair growth?

Certain peptides are designed to bind to receptors at the hair follicle, activating signals that support keratin production, strengthen the follicle’s structure, and help extend the hair’s natural growth phase.

If peptides aren’t supplements, what are they?

Peptides are short chains of amino acids that act as biological messengers. Instead of simply providing nutrients, they help support communication between cells and influence biological processes involved in growth, repair, and regeneration. In hair health, that means helping support the mechanisms that contribute to stronger, healthier hair growth.

Can you use peptides and minoxidil together?

Potentially, yes. Because they work in different ways, peptides and minoxidil may complement each other. Minoxidil can help stimulate follicle activity through increased blood flow, while peptides support the structure and function of the hair itself. Research is still evolving, but combination approaches are becoming more common as we better understand the multiple factors involved in hair loss.